Publications

Powered by Mass Cytometry

Publications from a variety of academic and industry groups, including work co-authored by Teiko scientists, demonstrate the critical role that peripheral blood plays in the treatment of cancer

Cancer | Published by Teiko

Mass cytometry immune profiling to detect signatures of clinical activity of bintrafusp alfa in patients with advanced non-small cell lung cancer

McAdams & Medina et al. ASCO (2023)

In this abstract published as part of ASCO 2023, McAdams & Medina et al. present data on immune signatures of clinical activity in patients with advanced NSCLC treated with bintrafusp alfa, a bifunctional anti-PDL1 / TGF-beta trap.

Read Highlights

Cancer | Published by Teiko

Immune features associated with clinical benefit and adverse events in response to immunotherapy in UC patients

Healy & Sweere et al. Cancer Res (2023)

Teiko scientists Drs. Healy & Sweere presented at AACR 2023 on immune features of immune-related adverse events and anti-PD1 response in blood in patients with urothelial carcinoma. These data were generated through a collaboration between the Parker Institute for Cancer Immunotherapy and Teiko Bio.

Read Highlights

Cancer | Published by Teiko

Peripheral immune features associated with severe adverse events in melanoma

Healy & Kovacsovics-Bankowski et al. SITC (2022)

Drs. Healy (Teiko Bio) & Kovacsovics-Bankowski (Huntsman Cancer Institute) presented at SITC 2022 on immune signatures of severe immune-related adverse events in blood in patients with advanced melanoma treated with immunotherapy. This data was generated through a collaboration between Dr. Siwen Hu-Lieskovan of the Huntsman Cancer Institute and Teiko Bio.

Read Highlights

COVID-19 | Teiko co-authors

Mass cytometry reveals a conserved immune trajectory of recovery in hospitalized COVID-19 patients

Burnett, Okholm, & Tenvooren, et al. Immunity (2022)

Burnett, Okholm, & Tenvooren, et al. use immune profiling by mass cytometry to identify an immune trajectory associated with COVID recovery and immune subsets associated with a requirement for mechanical ventilation

Read Highlights

Cancer | Teiko co-authors

Single-cell analysis by mass cytometry reveals metabolic states of early-activated CD8+ T cells during the primary immune response

Levine & Hiam-Galvez et al. Immunity. (2021)

Levine & Hiam-Galvez et al. use mass cytometry to profile metabolic states of early-activated CD8 T cells during infection and non-Hodkins lymphoma.

Read Highlights

Breast | Teiko co-authors

Systemic dysfunction and plasticity of the immune macroenvironment in cancer models

Allen & Hiam et al. Nature Medicine. (2020)

Allen & Hiam et al. use mass cytometry to define changes in immune cell frequencies and states across five tissue types in eight different mouse tumor models.

Read Highlights

Infographic hierarchy with an outline of a human at the top level. The second level has two groups, Peripheral Blood and Tumor Biopsy. The third level has different types of immune cells: T cells, B cells, NK cells, Monocytes, and Granulocytes. The fourth level has all of the subsets within each cell type listed as text. There are roughly 9 T cell subsets, 4 B cell subsets, 2 NK subsets, 8 Monocyte (and macrophage) subsets, and 4 Granulocyte subsets.

GvHD | Teiko co-authors

Comprehensive immune monitoring of clinical trials to advance human immunotherapy

Hartmann et al. Cell Rep (2019)

Hartmann et al. describes the development and utilization of a comprehensive and easily customizable 33-marker mass cytometry panel optimized for immune monitoring of clinical trials.

Read Highlights

Breast | Teiko co-authors

Systemic immunity Is required for effective cancer immunotherapy

Spitzer, Carmi, & Reticker-Flynn et al. Cell (2017)

In this seminal Cell 2017 publication, Spitzer, Carmi & Reticker-Flynn et al. show that effective immunotherapy treatment requires peripheral immune cell engagement in both breast and colon cancer mouse models.

Read Highlights

Graphical abstract. The top half is labeled "Baseline" and the bottom half is labeled "anti-PD-L1 ICB". On top there is a lymph node labeled "uninvolved regional lymph node" with 2 dendritic cells, 3 pairs of Tpex cells, 2 Tex-int cells, and 1 Treg. The bottom (anti-PD-L1 ICB) is split in half with each side containing a lymph node and blood vessel and a vertical dotted line separating the two. The lymph node on the left looks similar to above, but with more Tex-int cells and these all have a yellow dot representing KI-67 within them. The blood streaam also has three of these KI-67+ Tex-int cells. On the right this lymph node is labeled "metastatic" and has a big mass of cancer cells blocking most of the lymph node. What remains is a single cell of each type (DC, Tpex, Tex-int, and Treg) and the Tex-int cell does not have KI-67. In the blood vessel is a single Tex-int cell without KI-67.

Cancer | Teiko co-authors

Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes

Rahim, Okholm, & Jones et al. Cell (2023)

Rahim, Okholm, & Jones et al. show that immune checkpoint blockade activates CD8 T cell differentiation and proliferation in the lymph node, not within the tumor microenvironment, and these cells can be detected in transit via blood profiling.

Read Highlights